PANEL 08 // THE PUBLISHER
About the BPC-157 TB-500 verification terminal
An independent editorial project that scans the published research and the regulatory record against their sources — no clinic, no counter, no product.
What this site is
Wolverine Legit is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 blend and its two constituents. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and the public regulatory record.
The design borrows the grammar of an intrusion-detection console — the terminal a security analyst uses to scan traffic against a rule set and flag what does not match. That is the right register for this subject. The blend is a deck of discrete, single-compound, largely-rodent findings paired with an honest regulatory record, and we render each constituent as its own monitored channel rather than blurring the two into a sales pitch. "Wolverine" is a research-community nickname for a marketed combination, not a defined drug, and we treat it as such throughout.
What 'legit' means here
The word "legit" in this domain is a due-diligence posture, not a claim about services. It means we foreground the things a careful reader actually needs to verify: whether the evidence is real (mostly preclinical and single-compound), whether the synergy is proven (it is not), whether the combination has human data (it does not), and where the regulatory record stands (both components are currently FDA 503A Category 2, with a scheduled 2026 advisory-committee review) [6][9][10].
We do not sell the blend, recommend a dose, or point to a vendor. When we describe how legally compounded peptide access works, we describe the general pathway and its current constraints — not a route around them. The "legit" in our name is the analyst's register: scan the claim, check it against the source, and flag the gap rather than paper over it.
How we cite
Every quantitative claim on this site maps to a numbered entry in the references register, with a DOI or PubMed link. Where a finding comes from full-length Thymosin Beta-4 rather than the TB-500 heptapeptide, we say so, because that identity gap is one of the most important caveats for anyone reading about this blend [4][5]. Where a claim could not be confirmed from an authoritative source — including unverified reports of a 2026 reclassification or specific dated removals from Category 2 — we leave it out and state the last confirmable status instead.
That last rule is why the regulatory packet reads the way it does. We report the current FDA position (503A Category 2 for both components) and the one scheduled, citable future event (the July 2026 advisory-committee discussion), and we decline to assert any outcome of that meeting as decided [9][10]. It is the difference between reporting the record and predicting it, and an editorial project earns the word "legit" by staying on the first side of that line.